SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 2183-2189. Prepublished online as a Blood First Edition Paper on October 31, 2006; DOI 10.1182/blood-2006-07-033142. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-07-033142v1 109/5/2183    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bossard, C. Articles by Gaulard, P. Search for Related Content PubMed PubMed Citation Articles by Bossard, C. Articles by Gaulard, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 7, 2006 Accepted October 4, 2006 Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma : results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Celine Bossard, Karim Belhadj, Felix Reyes, Nadine Martin-Garcia, Francoise Berger, Jean Alain Kummer, Josette Briere, Anne-Catherine Baglin, Stephane Cheze, Jacques Bosq, Vincent Ribrag, Christian Gisselbrecht, Nicolas Mounier, and Philippe Gaulard* Departement de Pathologie et Inserm U617, Hopital Henri Mondor, France Service d'Hematologie Clinique, Hopital Henri Mondor, Creteil, France Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier Lyon Sud, Pierre Benite, France Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands Departement de Pathologie, Hopital Saint Louis, Paris, France Departement de Pathologie, Hopital Foch, Suresnes, France Service d'Hematologie Clinique, Hopital Clemenceau, Caen, France Departement de Pathologie, Institut Gustave Roussy, Villejuif, France Departement de Medecine, Institut Gustave Roussy, Villejuif, France Institut d'Hematologie, Hopital Saint-Louis, Paris, France * Corresponding author; email: philippe.gaulard{at}hmn.aphp.fr. Nasal NK/T-cell lymphoma is a rare disease entity with a poor outcome. Expression of antiapoptotic proteins has not been extensively investigated in this entity. Fourty-eight patients with nasal T/NK-cell lymphoma who received first line polychemotherapy (n=44) or chemoradiotherapy (n=4) were analyzed for expression of active caspase 3 (aC-3), granzyme B-protease inhibitor 9 (PI9) and Bcl-2 proteins. Lymphomas were CD3+/CD5-/Granzyme B+ and EBV-associated. Median age was 46 years. Stage I/II disease was present in 75% of the cases and an IPI score <1 in 65%. With a median follow-up of 6.3 years, 5y-event-free (EFS) and overall (OS) survivals were 39% and 49%, respectively. Apoptotic index (AI) was scored as high in 32% of cases and PI9 expression as positive in 68%, whereas 35% disclosed a high number of aC-3 positive tumor cells. Univariate analysis showed that absence of PI9 and low AI were associated with poor outcome, but not aC-3 expression nor IPI score. By multivariate analysis, both parameters affected independently EFS (p=0.02 and 0.08, respectively) and OS (p=0.009 and 0.04). In view of its constitutive expression by normal NK cells, it is suggested that loss of PI9 expression in tumor cells may reflect some mechanism associated with progression. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020